title: Non-invasive diagnostic and functional evaluation of cardiac involvement in patients with systemic sclerosis.
abstract: Elevated serum brain natriuretic peptide (BNP) released from myocytes of ventricles upon stretch have been found in patients with isolated right ventricular (RV) pressure overload. However, limited data suggest that serum BNP may be elevated in systemic sclerosis (SSc) patients, especially with RV dysfunction. We assessed serum N-terminal proBNP (NT-proBNP) in SSc and evaluated whether it reflects the severity of RV overload. We prospectively studied 51 consecutive patients (47F, mean age 53.3 +/- 15.2 years) with SSc (mean disease duration 9 +/- 12.4 years). The control group formed 31 healthy subjects (27F, mean age 52.6 +/- 12.1 years). NT-proBNP level, 6-minute walking test (6MWT), and transthoracic echocardiography (TTE) for the assessment of RV overload were performed. Serum NT-proBNP exceeded the reference value of 125 pg/mL in 31 (61%) SSc patients. The mean serum log NT-proBNP concentration in SSc was higher than in controls (2.138 +/- 0.527 vs. 1.634 +/- 0.420 pg/mL, p < 0.001). 13 (25%) SSc patients have tricuspid regurgitation peak gradient (TRPG) exceeding 31 mmHg reflecting pulmonary arterial hypertension (PAH). The SSc presented other echocardiographic signs of RV overload. Mean 6MWT distance was shorter in SSc than in controls (528 +/- 100 vs. 617 +/- 80 m, p < 0.001). NT-proBNP level correlated positively with TRPG, RV diameter, RV Tei index and negatively with 6MWT distance. ROC analysis identified >115 pg/ml as the best NT-proBNP threshold predicting PAH for SSc patients (sensitivity 92%, specificity 44%). Results of our study suggest that NT-proBNP measurement is a useful screening method for PAH in SSc patients. Since elevated plasma NT-proBNP level reflects the degree of right ventricular overload and limitation of exercise capacity, abnormal NT-proBNP levels should imply further evaluation including echocardiography.
authors.affiliation: Department of Internal Medicine and Cardiology, Institute of Dentistry, Medical University of Warsaw, Lindleya 4, 02-005, Warsaw, Poland. mciurzyn@amwaw.edu.pl
authors.forename: Michał
authors.initials: M
authors.lastname: Ciurzyński
authors.forename: Piotr
authors.initials: P
authors.lastname: Bienias
authors.forename: Barbara
authors.initials: B
authors.lastname: Lichodziejewska
authors.forename: Katarzyna
authors.initials: K
authors.lastname: Kurnicka
authors.forename: Agnieszka
authors.initials: A
authors.lastname: Szewczyk
authors.forename: Maria
authors.initials: M
authors.lastname: Glińska-Wielochowska
authors.forename: Marcin
authors.initials: M
authors.lastname: Kurzyna
authors.forename: Maria
authors.initials: M
authors.lastname: Błaszczyk
authors.forename: Danuta
authors.initials: D
authors.lastname: Liszewska-Pfejfer
authors.forename: Piotr
authors.initials: P
authors.lastname: Pruszczyk
mesh_terms: D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D004452:Echocardiography; D005080:Exercise Test; D005260:Female; D006801:Humans; D006976:Hypertension, Pulmonary / Q000097:blood* / Q000150:complications; D008297:Male; D008875:Middle Aged; D020097:Natriuretic Peptide, Brain / Q000097:blood*; D011446:Prospective Studies; D012595:Scleroderma, Systemic / Q000097:blood* / Q000150:complications; D018497:Ventricular Dysfunction, Right / Q000097:blood / Q000150:complications
chemical_list: D015415:Biomarkers; D020097:Natriuretic Peptide, Brain